NCT07583992尚未招募2 期
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
National Research Institute of Chinese Medicine, Ministry of Health and Welfare1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are:
- Does NRICM102 help participants reach clinical stability faster compared to placebo?
- What medical problems do participants have when taking NRICM102?
Researchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia.
Participants will:
- Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days
- Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations
- Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged 18 to 85 years
- •The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria:
- •Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (<35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹/L or less than 4×10⁹/L
- •Subjects requiring hospitalization and intravenous antibiotic therapy
- •Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission
- •Subjects who are able to take the investigational product orally
- •Subjects who are able to understand and comply with all study procedures and provide written informed consent
排除标准
- •Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction
- •Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission
- •Subjects who have been hospitalized within 15 days prior to current admission
- •Subjects with aspiration pneumonia
- •Subjects requiring admission to the intensive care unit (ICU)
- •Subjects requiring hemodialysis
- •Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history)
- •Subjects with human immunodeficiency virus (HIV) infection
- •Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants
- •Subjects requiring antiviral agents for COVID-19 infection or influenza
- •Subjects must be on a stable dose of Omeprazole or Warfarin
- •Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history)
- •Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation/study time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include:
- •Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs).
- •Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.*
- •Combination of two barrier methods.* *Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals).
- •Subjects deemed unsuitable for study participation by the investigator
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
A Randomised Pilot Trial Evaluating a Chinese Medicine Formula in the Treatment of Chronic Subjective TinnitusChiCTR2100046632Hong Kong Health and Medical Research Fund24
尚未招募
4 期
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese PatientsPlaque PsoriasisPsoriasisNCT07485764Union Hospital, Tongji Medical College, Huazhong University of Science and Technology186
招募中
1 期
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.NCT07258979MediLink Therapeutics (Suzhou) Co., Ltd.202
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
招募中
不适用
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerNCT07356531JIANGSU SHENMING Medical Technology CO., Ltd216